

Imugene appoints Dr Rita Laeufle as Chief Medical Officer

Sydney, Australia, 30 September 2020: Imugene Limited (ASX:IMU) a clinical stage immuno-oncology company today announced the appointment of Dr Rita Laeufle, MD PhD, as Chief Medical Officer (CMO) and a member of the Company's executive leadership team.

Dr Laeufle will lead the Company's global clinical development, regulatory and medical monitoring activities, replacing Dr Mark Marino who is stepping down from his position.

As a board-certified surgical oncologist and a scientist, Dr Laeufle has extensive clinical development experience in immuno-oncology studies from Phase 1 to Phase 3 in breast and gastrointestinal cancers registration pathways. Dr Laeufle brings deep experience to the Company, having held senior level clinical development, leadership and senior medical positions at top tier pharmaceutical companies, including Hoffman-La Roche AG, and Novartis Pharmaceuticals Corp. Most recently she was the CMO at leading oncolytic virus company Oncolytics Biotech in San Diego CA, where she will be based.

Dr Laeufle holds Medical Doctor and Doctor of Philosophy degrees from the Albert Ludwig University Freiburg i.Br. Germany. Her PhD subject was expression of neu/c-erbB-2 (HER-2) in human brain tumors. (Magna cum Laude).

Dr. Laeufle stated, "Today, our knowledge and understanding of cancer biology has reached new dimensions. Scientists from all over the world, with their passion and enthusiasm, have provided us a future of new immunotherapy agents that will help cure and ease the burden of dreadful disease. With a pipeline of innovative immunotherapy vaccines and oncolytic viruses, I am enthusiastic to join this wonderful team of experts at Imugene. Together we will drive towards better and safer treatments for the benefit of patients."

Welcoming Dr Laeufle, Imugene Managing Director and CEO Leslie Chong said: "We look forward to the valuable contribution Dr Laeufle will make to advance our important immuno-oncology programs and are very pleased someone with her track record and experience is joining Imugene as Chief Medical Officer".

Imugene Executive Chairman Mr Paul Hopper said "Rita adds a critical capability to our senior leadership team, and we are pleased to welcome her to Imugene."

"We thank Dr. Mark Marino for his valuable contribution over the past two years and we wish him well in his future endeavours" he added.

For further information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
T: +61 458 040 433
E: Leslie.Chong@Imugene.com

Follow us on Twitter @TeamImugene
Like us on Facebook @Imugene
Connect with us on LinkedIn @Imugene Limited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets.

Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Office